SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name: Mometasone / Clotrimazole / Gentamicin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company: MSD Kilsheelan Clonmel Tipperary, IE
   Telephone: 353-51-601000
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1A: H360D: May damage the unborn child.
   Short-term (acute) aquatic hazard, Category 1: H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 2: H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms:  
   Signal word: Danger
   Hazard statements: H360D May damage the unborn child.
   H410 Very toxic to aquatic life with long lasting effects.
   Precautionary statements: Prevention:
   P201 Obtain special instructions before use.
Mometasone / Clotrimazole / Gentamicin Formulation

P273  Avoid release to the environment.
P280  Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313  IF exposed or concerned: Get medical advice/ attention.
P391  Collect spillage.

Storage:
P405  Store locked up.

Hazardous components which must be listed on the label:
Gentamicin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>245-764-8</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302</td>
<td>Acute Tox. 3; H311</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Irrit. 2; H319</td>
<td>Eye Irrit. 2; H319</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Rep. 2; H361fd</td>
<td>Acute Rep. 2; H361fd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STOT RE 2; H373</td>
<td>STOT RE 2; H373</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver, Kidney, Adrenal gland</td>
<td>Liver, Kidney, Adrenal gland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Acute 1; H400</td>
<td>Aquatic Acute 1; H400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic 1; H410</td>
<td>Aquatic Chronic 1; H410</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Acute aquatic toxicity): 10</td>
<td>M-Factor (Acute aquatic toxicity): 10</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin For- 
mulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020

Date of first issue: 14.12.2015

<table>
<thead>
<tr>
<th></th>
<th>M-Factor (Chronic aquatic toxicity): 10</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentamicin</td>
<td></td>
<td>0,5</td>
</tr>
<tr>
<td></td>
<td>Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M-Factor (Acute aquatic toxicity): 100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M-Factor (Chronic aquatic toxicity): 1</td>
<td></td>
</tr>
<tr>
<td>Mometasone</td>
<td></td>
<td>0,1</td>
</tr>
<tr>
<td></td>
<td>Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M-Factor (Chronic aquatic toxicity): 100</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

<table>
<thead>
<tr>
<th>If swallowed</th>
<th>If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.</th>
</tr>
</thead>
</table>

### 4.2 Most important symptoms and effects, both acute and delayed

Risks: May damage the unborn child.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil</td>
<td>8042-47-5</td>
<td>TWA (Vapour)</td>
<td>50 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist and particles)</td>
<td>1 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection

Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: suspension
Colour: white to off-white
Odour: oily
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Decomposition temperature: No data available
pH: No data available
Viscosity

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Mometasone / Clotrimazole / Gentamicin Formulation

Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable
Vapour pressure : No data available

Relative density : No data available
Density : No data available
Relative vapour density : No data available

Particle characteristics
Particle size : Not applicable

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

clotrimazole:
Acute oral toxicity: LD50 (Rat): 708 mg/kg
LD50 (Mouse): 761 mg/kg
LD50 (Rabbit): > 1.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0,73 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Mouse): 923 mg/kg

Gentamicin:
Acute oral toxicity: LD50 (Rat): 8.000 - 10.000 mg/kg
LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 0,2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration):
LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous
LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular
LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

Mometasone:
Acute oral toxicity: LD50 (Rat): > 2.000 mg/kg
Mometasone / Clotrimazole / Gentamicin Formulation

LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity:
- LC50 (Rat): > 3,3 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
- Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l
- Exposure time: 4 h
- Test atmosphere: dust/mist

Acute toxicity (other routes of administration):
- LD50 (Rat): 300 mg/kg
- Application Route: Subcutaneous
- Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:

Clotrimazole:
- Species: Rabbit
- Result: No skin irritation

Gentamicin:
- Species: Rabbit
- Result: Mild skin irritation

Mometasone:
- Species: Rabbit
- Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Clotrimazole:
- Species: Rabbit
- Result: Mild eye irritation

Gentamicin:
- Species: Rabbit
- Result: Mild eye irritation

Mometasone:
- Species: Rabbit
- Result: No eye irritation
Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Gentamicin:
Remarks: No data available

Mometasone:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitisation.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity
Not classified based on available information.

Components:

Clotrimazole:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: in vitro micronucleus test  
Result: negative

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Application Route: Oral  
Result: negative

Test Type: Mammalian spermatogonial chromosome aberration test (in vivo)  
Species: Hamster  
Result: negative

Germ cell mutagenicity: Assessment  
Weight of evidence does not support classification as a germ cell mutagen.
Mometasone / Clotrimazole / Gentamicin Formulation

<table>
<thead>
<tr>
<th>Gentamicin:</th>
<th>Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: Chromosome aberration test in vitro Result: equivocal</td>
</tr>
<tr>
<td>Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intravenous injection Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mometasone:</th>
<th>Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative</td>
</tr>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive</td>
</tr>
<tr>
<td></td>
<td>Test Type: Mouse Lymphoma Result: negative</td>
</tr>
<tr>
<td>Genotoxicity in vivo: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative</td>
</tr>
<tr>
<td></td>
<td>Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity: Assessment Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.
**Components:**

**Clotrimazole:**
- **Species:** Rat
- **Application Route:** Oral
- **Exposure time:** 78 weeks
- **Result:** negative

**Gentamicin:**
- **Carcinogenicity - Assessment:** No data available

**Mometasone:**
- **Species:** Rat
- **Application Route:** Inhalation
- **Exposure time:** 2 Years
- **Dose:** 0.067 mg/kg body weight
- **Result:** negative

**Species:** Mouse
- **Application Route:** Inhalation
- **Exposure time:** 19 Months
- **Dose:** 0.160 mg/kg body weight
- **Result:** negative

**Reproductive toxicity**
May damage the unborn child.

**Components:**

**Clotrimazole:**
- **Effects on fertility:** Test Type: Fertility/early embryonic development
  - **Species:** Rat
  - **Application Route:** Oral
  - **Fertility:** LOAEL: 50 mg/kg body weight
  - **Result:** Effects on fertility

- **Effects on foetal development:** Test Type: Embryo-foetal development
  - **Species:** Rat
  - **Application Route:** Oral
  - **Developmental Toxicity:** LOAEL: 100 mg/kg body weight
  - **Result:** Embryo-foetal toxicity, No teratogenic effects
  - **Test Type:** Embryo-foetal development
    - **Species:** Rat
    - **Application Route:** Oral
    - **Developmental Toxicity:** NOAEL: 50 mg/kg body weight
    - **Result:** Embryo-foetal toxicity, No teratogenic effects

- **Test Type:** Embryo-foetal development
  - **Species:** Mouse
  - **Application Route:** Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 180 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

Gentamicin:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: NOAEL: 3,6 mg/kg body weight
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 75 mg/kg body weight
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: Foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

Mometasone:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0,015 mg/kg body weight
Mometasone / Clotrimazole / Gentamicin Formulation

Symptoms: Reduced embryonic survival, Reduced foetal weight
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development:
- Test Type: Embryo-foetal development
  Species: Mouse
  Application Route: Subcutaneous
  Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight
  Result: Embryotoxic effects, Teratogenicity and developmental toxicity

- Test Type: Embryo-foetal development
  Species: Rat
  Application Route: Dermal
  Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
  Result: Embryo-foetal toxicity

- Test Type: Embryo-foetal development
  Species: Rabbit
  Application Route: Dermal
  Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  Result: Embryo-foetal toxicity, Malformations were observed.

- Test Type: Embryo-foetal development
  Species: Rat
  Application Route: Subcutaneous
  Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
  Result: Effects on newborn

- Test Type: Embryo-foetal development
  Species: Rabbit
  Application Route: Oral
  Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
  Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment:
- Clear evidence of adverse effects on development, based on animal experiments. Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:
Mometasone: Based on available data, the classification criteria are not met.

STOT - repeated exposure
Not classified based on available information.
Mometasone / Clotrimazole / Gentamicin Formulation

Components:

clotrimazole:
Target Organs: Liver, Kidney, Adrenal gland
Assessment: May cause damage to organs through prolonged or repeated exposure.

Gentamicin:
Target Organs: Kidney, inner ear
Assessment: Causes damage to organs through prolonged or repeated exposure.

Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

clotrimazole:
Species: Rabbit
LOAEL: 5 - 40 mg/kg
Application Route: Skin contact
Exposure time: 3 Weeks
Target Organs: Skin
Symptoms: Oedema, Fissuring, Necrosis, Redness

Species: Rat
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Liver, Kidney, Adrenal gland

Species: Dog
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 6 - 12 Months
Target Organs: Adrenal gland
Symptoms: Salivation, Lachrymation, Vomiting

Gentamicin:
Species: Dog
LOAEL: 3 mg/kg
Application Route: Intramuscular
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Vomiting, Salivation
Species: Monkey
LOAEL: 50 mg/kg
Application Route: Subcutaneous
Exposure time: 3 Weeks
Target Organs: Kidney, inner ear

Species: Monkey
LOAEL: 6 mg/kg
Application Route: Intramuscular
Exposure time: 3 Weeks
Target Organs: Blood, Kidney, inner ear, Liver

Species: Rat
NOAEL: 5 mg/kg
LOAEL: 10 mg/kg
Application Route: Intramuscular
Exposure time: 52 Weeks
Target Organs: Kidney, Blood

Species: Rat
NOAEL: 12.5 mg/kg
LOAEL: 50 mg/kg
Application Route: Intramuscular
Exposure time: 13 Weeks
Target Organs: Kidney

Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Dog
NOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin For-
mulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020

Date of first issue: 14.12.2015

Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone: Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

clotrimazole:
Skin contact: Symptoms: Rash, Itching, Blistering, Oedema, Redness
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:
Ingestion: Target Organs: Kidney, Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible
**SECTION 12: Ecological information**

### 12.1 Toxicity

**Components:**

**Clotrimazole:**
- **Toxicity to fish:**
  - LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:**
  - EC50 (Daphnia magna (Water flea)): 0.02 mg/l
  - Exposure time: 48 h
- **Toxicity to algae/aquatic plants:**
  - EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l
  - Exposure time: 72 h
  - NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l
  - Exposure time: 72 h
- **M-Factor (Acute aquatic toxicity):** 10
- **Toxicity to microorganisms:**
  - EC50: > 10,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
- **Toxicity to fish (Chronic toxicity):**
  - NOEC: 0.025 mg/l
  - Exposure time: 32 d
  - Species: Oncorhynchus mykiss (rainbow trout)
  - Method: OECD Test Guideline 210
- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):**
  - NOEC: 0.01 mg/l
  - Exposure time: 21 d
  - Species: Daphnia magna (Water flea)
  - Method: OECD Test Guideline 211
- **M-Factor (Chronic aquatic toxicity):** 10

**Gentamicin:**
- **Toxicity to daphnia and other aquatic invertebrates:**
  - EC50 (Daphnia magna (Water flea)): 86 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - LC50 (Americamysis): 30 mg/l
  - Exposure time: 96 h
- **Toxicity to algae/aquatic plants:**
  - EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
  - Exposure time: 72 h
**SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

**Mometasone / Clotrimazole / Gentamicin Formulation**

**Version**: 4.5  
**Revision Date**: 09.04.2021  
**SDS Number**: 415344-00016  
**Date of last issue**: 10.10.2020  
**Date of first issue**: 14.12.2015

**Method**: OECD Test Guideline 201

**NOEC** (Pseudokirchneriella subcapitata (green algae)): 1,5 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**EC50** (Anabaena flos-aquae (cyanobacterium)): 4,7 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**NOEC** (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**M-Factor (Acute aquatic toxicity)**: 100

**Toxicity to microorganisms**:  
**EC50**: 288,7 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**M-Factor (Chronic aquatic toxicity)**: 1

**Mometasone**:

**Toxicity to fish**:  
**LC50** (Menidia beryllina (Silverside)): 0,11 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility

**LC50** (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility

**Toxicity to daphnia and other aquatic invertebrates**:  
**EC50** (Daphnia magna (Water flea)): > 5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility

**EC50** (Americamysis): > 5 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility

**Toxicity to algae/aquatic plants**:  
**EC50** (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

**Toxicity to microorganisms**:  
**EC50**: > 1.000 mg/l  
Exposure time: 3 h
Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5  Revision Date: 09.04.2021  SDS Number: 415344-00016  Date of last issue: 10.10.2020  Date of first issue: 14.12.2015

Test Type: Respiration inhibition  Method: OECD Test Guideline 209  Remarks: No toxicity at the limit of solubility

NOEC: 1.000 mg/l  Exposure time: 3 h  Test Type: Respiration inhibition  Method: OECD Test Guideline 209  Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity):

NOEC: 0.00014 mg/l  Exposure time: 32 d  Species: Pimephales promelas (fathead minnow)  Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

NOEC: 0.34 mg/l  Exposure time: 21 d  Species: Daphnia magna (Water flea)  Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 100

12.2 Persistence and degradability

Components:

clotrimazole:

Stability in water: Hydrolysis: 50% (242 d)

Gentamicin:

Biodegradability: Result: rapidly degradable  Biodegradation: 100%  Exposure time: 28 d  Method: OECD Test Guideline 314

Mometasone:


Stability in water: Hydrolysis: 50% (12 d)  Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Gentamicin:

Partition coefficient: n-Octanol/Water: log Pow: < -2
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020 Date of first issue: 14.12.2015

octanol/water

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107,1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4,68

12.4 Mobility in soil

Components:

Mometasone:
Distribution among environmental compartments: log Koc: 4,02

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:
Endocrine disrupting potential: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5     Revision Date: 09.04.2021     SDS Number: 415344-00016     Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>Mode</th>
<th>UN Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
</tr>
<tr>
<td>ADR</td>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3082</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
</tr>
<tr>
<td>IATA</td>
<td></td>
<td>Environmentally hazardous substance, liquid, n.o.s. (clotrimazole, Gentamicin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>Mode</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>9</td>
</tr>
<tr>
<td>ADR</td>
<td>9</td>
</tr>
<tr>
<td>RID</td>
<td>9</td>
</tr>
<tr>
<td>IMDG</td>
<td>9</td>
</tr>
<tr>
<td>IATA</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th>Mode</th>
<th>Packing group</th>
<th>Classification Code</th>
<th>Hazard Identification Number</th>
<th>Labels</th>
<th>Tunnel restriction code</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADN</td>
<td>III</td>
<td>M6</td>
<td>90</td>
<td>9</td>
<td>(-)</td>
</tr>
<tr>
<td>ADR</td>
<td>III</td>
<td>M6</td>
<td>90</td>
<td>9</td>
<td>(-)</td>
</tr>
<tr>
<td>RID</td>
<td>III</td>
<td>M6</td>
<td></td>
<td></td>
<td>(-)</td>
</tr>
</tbody>
</table>
Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5     Revision Date: 09.04.2021     SDS Number: 415344-00016     Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, : Conditions of restriction for the following entries should be considered:
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5 Revision Date: 09.04.2021 SDS Number: 415344-00016 Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

preparations and articles (Annex XVII)
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
REACH - List of substances subject to authorisation (Annex XIV)
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

Number on list 3
Quantity 1 100 t
Quantity 2 200 t

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302: Harmful if swallowed.
H311: Toxic in contact with skin.
H319: Causes serious eye irritation.
H360D: May damage the unborn child.
H360Df: May damage the unborn child. Suspected of damaging fertility.
H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5
Revision Date: 09.04.2021
SDS Number: 415344-00016
Date of last issue: 10.10.2020
Date of first issue: 14.12.2015

H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
FOR-2011-12-06-1358 : Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / : Long term exposure limit
TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information
Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.5  Revision Date: 09.04.2021  SDS Number: 415344-00016  Date of last issue: 10.10.2020
Date of first issue: 14.12.2015


Classification of the mixture:
- Repr. 1A: H360D  Calculation method
- Aquatic Acute 1: H400  Calculation method
- Aquatic Chronic 2: H411  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN